Different positions of BMS, Gilead and Abbvie over hepatitis C guideline

Disease guidelines are important to pharmaceutical companies. They can be even more important for recently-launched drugs.

This is why the industry has paid attention to the hepatitis C guideline which was recently announced at the Korean Association for the Study of the Liver’s(KASL) public hearing. Without any objection, the society will confirm the guideline and officially announce it at it...